Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Organto reported solid Q2 financials, with revenue coming in at $27.7M (+61% YoY) vs. our estimate of $28.9M and EBITDA of $0.4M vs. our estimate of $0.3M.</li>
<li>Gross margin came in at 7.5% (in line with our estimates), improving QoQ but impacted by the ongoing conflict in the Middle East.</li>
<li>Management will be hosting an investor webinar on August 13th at 12:00 PM EST.</li>
</ul>


Organto reported solid Q2 financials, with revenue coming in at $27.7M (+61% YoY) vs. our estimate of $28.9M and EBITDA of $0.4M vs. our estimate of $0.3M.
Gross margin came in at 7.5% (in line with our estimates), improving QoQ but impacted by the ongoing conflict in the Middle East.
Management will be hosting an investor webinar on August 13th at 12:00 PM EST.


OGO: 2nd Consecutive Quarter of Positive EBITDA; Sales Up 61%

Organto Foods

OGO: 2nd Consecutive Quarter of Positive EBITDA; Sales Up 61%